- Revenue Cycle Management
- COVID-19
- Reimbursement
- Diabetes Awareness Month
- Risk Management
- Patient Retention
- Staffing
- Medical Economics® 100th Anniversary
- Coding and documentation
- Business of Endocrinology
- Telehealth
- Physicians Financial News
- Cybersecurity
- Cardiovascular Clinical Consult
- Locum Tenens, brought to you by LocumLife®
- Weight Management
- Business of Women's Health
- Practice Efficiency
- Finance and Wealth
- EHRs
- Remote Patient Monitoring
- Sponsored Webinars
- Medical Technology
- Billing and collections
- Acute Pain Management
- Exclusive Content
- Value-based Care
- Business of Pediatrics
- Concierge Medicine 2.0 by Castle Connolly Private Health Partners
- Practice Growth
- Concierge Medicine
- Business of Cardiology
- Implementing the Topcon Ocular Telehealth Platform
- Malpractice
- Influenza
- Sexual Health
- Chronic Conditions
- Technology
- Legal and Policy
- Money
- Opinion
- Vaccines
- Practice Management
- Patient Relations
- Careers
1 in 4 worried about holiday COVID; Flu soars in 7 states; Cough medicine prototype struck down - Morning Medical Update
The top news stories in primary care today.
doctor morning desk © Alena Kryazheva - stock.adobe.com
1 in 4 worried about holiday COVID
Only 1 in 4 Americans are worried about catching COVID this holiday season, a new survey shows. Similarly, 3 in 10 are worried about spreading COVID to their loved ones. Vaccine awareness is highest in those ages 65 and older.
Flu rates have begun to rise most rapidly in Louisiana, followed by Alabama, Florida, Georgia, Mississippi, New Mexico, and South Carolina according to data from the Centers for Disease Control and Prevention. In Puerto Rico, officials have declared the flu an epidemic. The CDC estimates at least 780,000 cases this year with at least 8,000 hospitalizations and at least 490 flu-related deaths. “We’re off to the races,” Dr. William Schaffner, a Vanderbilt University infectious diseases expert said in a news release.
Cough medicine prototype struck down
The U.S. Food and Drug Administration (FDA) panel voted against Merck’s new cough medicine gefapixant 12 to 1. Data shows 22% of patients discontinued use due to side effects such as loss of taste. Merck said there is currently no medicine for chronic cough which affects 5% to 10% of the global adult population.
